Fenofibrate in Patients With Cervical Intraepithelial Neoplasia and Invasive Cervical Carcinoma

Inclusion Criteria:

• Participants must have histologically or cytologic confirmed high grade dysplasia orcervical cancer. Histologic types include squamous cell, adenocarcinoma oradenosquamous cell carcinoma.

• Participants must be eligible for surgical management with LEEP, CKC or hysterectomyor chemoradiation

• Age ≥ 18 years

• Normal liver function (AST, ALT, bilirubin within institutional normal limits).

• Participants must be English speaking

• Participants must have the ability to understand and the willingness to sign awritten informed consent document.

Exclusion Criteria:

• Participants with active liver disease, including primary biliary cirrhosis andunexplained, liver function abnormality

• Participants with severe kidney impairment (CrCl ≤30 mL/min calculated usingCockcroft-Gault), or end-stage kidney disease on dialysis

• Participants with preexisting gallbladder disease including active gallstones

• Known hypersensitivity to fenofibrate or fenofibric acid

• Participants that are pregnant or breast feeding due to unknown risk to developingfetus/infant. Please note: Participants of child-bearing potential (have had menseswithin the past year or have not had total hysterectomy) are actively screened forpregnancy prior to diagnostic procedures and screened again prior to treatment.